TOX and the Tumor Microenvironment in Immunotherapy

Description: James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses promising approaches for looking at tumor microenvironment. He mentions a study that showed patients who received standard of care therapy plus immunotherapy had a better response rate than those who only received standard of care. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Shared By : AnnualMeeting-SITC2017
Posted on : 03/06/17
Added : 9 months ago
Category : Immunotherapy


Nothing found.

More From AnnualMeeting-SITC2017

Nothing found.